clinical trial · NCT03244072
Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
Jason Ahee, M.D.·phase3·not yet recruiting·n = 60,000
EndophthalmitisMoxifloxacinPlacebo
brief summary
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis
started
Jun 1, 2026
primary completion
Oct 1, 2030
completion
Oct 1, 2031
last updated
Sep 25, 2025
detailed description
Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.
official title
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol